Multi-center, double-blind, randomized study to investigate the impact of a sequential oral contraceptive containing estradiol valerate and dienogest (SH T00658ID) compared to a monophasic contraceptive containing ethinylestradiol and levonorgestrel (Microgynon) over 6 treatment cycles on alleviating complaints of reduced libido in women with acquired female sexual dysfunction (FSD) associated with oral contraceptive use”Estudio multicéntrico, doble ciego, aleatorizado para investigar el impacto de un anticonceptivo oral secuencial que contiene estradiol valerate y dienogest ( SH T00658ID) comparado con un anticonceptivo monofásico que contiene etinilestradiol y levonorgestrel ( Microgynon) en 6 ciclos de tratamiento en el alivio de las quejas de disminución de la libido en las mujeres con disfunción sexual femenina adquirida, asociada con el uso de anticonceptivos orales.

Bayer HealthCare AG0 个研究点目标入组 216 人2008年11月27日

概览

阶段: 不适用
干预措施: 未指定
疾病 / 适应症: Reduced libido in women with acquired female sexual dysfunction (FSD) associated with oral contraceptive use.Disminución de la libido en mujeres con disfunción sexual femenina adquirida, asociada con el uso de anticonceptivos orales.
发起方: Bayer HealthCare AG
入组人数: 216
状态: 进行中（未招募）
最后更新: 11年前

暂无简介。

注册库

who.int

开始日期

2008年11月27日

结束日期

待定

最后更新

11年前

研究类型

Interventional clinical trial of medicinal product

性别

Female

发起方

•1\.Signed and dated informed consent
•2\.Age between 18 and 50 years (inclusive), smokers maximum age of 30 years (inclusive) at Visit 1
•3\.At screening, the subject must be on the OC which has caused the libido complaints according to their perception. All marketed OCs of the monophasic combined oral contraceptive type (COC), including Microgynon, will be allowed.
•4\.Must be suffering from reduced libido as a perceived side effect of the OC use (ie, acquired OC\-associated FSD) for at least three months, but not longer than one year, and willing to switch to the randomly assigned study treatment (SH T00658ID or Microgynon)
•5\.Value of 18 or below in the not weighted sum score of FSFI sexual desire and sexual arousal component scores, defined as the total of questions 1 to 6 of the FSFI at Screening and Baseline
•6\.Sexual relationship with a sexually competent partner
•7\.Normal or clinically insignificant cervical smear not requiring further follow up (a cervical smear has to be taken at screening visit or a normal result has to be documented within the last 6 months before screening)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes

•1\) Female sexual dysfunction such as sexual aversion/phobic disorder, sexual pain disorder/dyspareunia
•2\) Hyperandrogenemic conditions, such as congenital adrenal hyperplasia (CAH), polycystic ovary syndrome (PCOS), Cushing’s syndrome or signs of hyperandrogenism like severe hirsutism or severe acne
•3\) Pregnancy, lactation (at least three cycles have to follow delivery, abortion, or lactation before start of treatment)
•4\) Body mass index (BMI) \>32 kg/m2
•5\) Hypersensitivity to any of the study drug ingredients
•6\) Vegetarians/ individuals not consuming pork and beef products. Women may be included if they are willing to take the capsules.
•7\) Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study medication (such as but not limited to duodenal ulcers, gastritis, gastrectomy or gastric resection surgery, or renal compromise)
•8\) Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results (eg, depression, anxiety, other psychiatric diseases)
•9\) Any disease or condition that may worsen under hormonal treatment (refer to protocol Section 8\.7\.2 for details)
•10\) Undiagnosed abnormal genital bleeding